Citation: Future Science OA. 4(1):FSO249, 2018 Jan.Journal: Future science OA.Published: 2018ISSN: 2056-5623.Full author list: Jonklaas J; Murthy S; Liu D; Klubo-Gwiezdzinska J; Krishnan J; Burman KD; Boyle L; Carrol N; Felger E; Loh YP.UI/PMID: 29255621.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Pathology | Medicine/Endocrinology | Surgery/General Surgery | Surgery/Endocrine SurgeryActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.4155/fsoa-2017-0087 (Click here)Abbreviated citation: Future Sci OA. 4(1):FSO249, 2018 Jan.Abstract: Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.Abstract: Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.Abstract: Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.Abstract: Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.